Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claim is fully supported by the provided FDA label text: the boxed warning attributes thyroid C-cell tumor findings in rodents to semaglutide and states human relevance (including MTC) is unknown, with corroboration in Warnings (5.1) and Nonclinical Toxicology (13.1).
Category Scores
Accurate Statements
Thyroid C-cell tumors are a boxed-warning risk for OZEMPIC (semaglutide), with tumor findings in rodents and uncertainty for human relevance.
Boxed Warning states semaglutide causes dose- and treatment-duration-dependent thyroid C-cell tumors in rodents at clinically relevant exposures and it is unknown whether OZEMPIC causes thyroid C-cell tumors (including MTC) in humans; Warnings (5.1) and Nonclinical Toxicology (13.1) describe the rodent findings and conclude human relevance is unknown.
Unsupported Statements
Contradictions
Important Omissions
The label text specifies monitoring/counseling details (e.g., counsel symptoms; routine serum calcitonin/thyroid ultrasound of uncertain value; elevated calcitonin >50 ng/L) that are not included in the AI claim.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claim accurately reflects the boxed warning and related label uncertainty about human relevance; it does not add unsupported or contradictory information.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omission of label-specific counseling/monitoring statements contained in Boxed Warning/Warnings (5.1).
Suggested Improvement
When summarizing the boxed warning, also mention that the label advises counseling on symptoms and that routine calcitonin/ultrasound monitoring is of uncertain value for early detection.